New data from a post-hoc analysis of the TWILIGHT trial showed that, in patients who underwent a complex percutaneous coronary intervention (PCI) , ticagrelor monotherapy after an initial 3 months of dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin was associated with significantly lower clinically relevant bleeding without increasing the risk of ischaemic events compared with continuing the DAPT. The TWILIGHT-COMPLEX sub-study was presented by Prof. George Dangas (Icahn School of Medicine at Mount Sinai, USA) and published simultaneously [1,2].
The original randomised, double-blind, placebo-controlled TWILIGHT trial recently determined that dropping aspirin after 3 months of DAPT with ticagrelor following PCI is associated with lower rates of bleeding but no increased risk of death, myocardial infarction (MI), or stroke [3]. The aim of this sub-study was to evaluate the effect of ticagrelor monotherapy versus ticagrelor + aspirin in patients undergoing complex PCI, defined as a combination of high-risk angiographic and procedural features.
Of the original 9,006 participants in the original TWILIGHT trial, investigators considered 2,342 (33%) as requiring complex PCI. Complex PCI was defined as 3 or more lesions or vessels treated, total stent length greater than 60 mm, bifurcation with 2 stents implanted, atherectomy device use, left main PCI, surgical bypass graft, or chronic total occlusion as target lesions.
All participants underwent 1:1 randomisation to either ticagrelor + placebo or to ticagrelor + aspirin and had a 1-year follow-up. All patients received aspirin before randomisation for the first 3 months following PCI. Like the TWILIGHT trial, the primary endpoint of this post-hoc analysis was Bleeding Academic Research Consortium (BARC) 2, 3, or 5 bleeding, and investigators also assessed for a composite ischaemic endpoint of all-cause death, MI, or stroke.
Of the 2,342 patients who had had complex PCI, 1,158 were randomised to ticagrelor + placebo and 1,184 were randomised to ticagrelor + aspirin. Ticagrelor + placebo resulted in significantly lower rates of BARC type 2, 3, or 5 bleeding than ticagrelor + aspirin: 4.2% versus 7.7%, respectively (HR 0.54; 95% CI 0.38-0.76; P<0.001). BARC type 3 or 5 bleeding was also significantly reduced with ticagrelor + placebo (1.1%) compared with ticagrelor + aspirin (2.6%; HR 0.41; 95% CI 0.21-0.80; P=0.009).
This subgroup was not powered to assess differences in ischaemic outcomes between the 2 groups with results of death, MI, or stroke (3.8% vs 4.9%; HR 0.77; 95% CI 0.52-1.15) as well as cardiovascular death, MI, or stroke (3.6% vs 4.8%; HR 0.75; 95% CI 0.50-1.12). There were also no significant differences in all-cause deaths between groups (0.9% vs 1.5%; HR 0.59; 95% CI 0.27-1.29; see Table). In conclusion, this subset analysis established that withdrawing aspirin after complex PCI reduced bleeding.
Table. Bleeding and ischaemic events 1 year after randomisation. Modified from [2]
BARC, Bleeding Academic Research Consortium; CI, confidence interval; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; ISTH, International Society on Thrombosis and Haemostasis; MI, myocardial infarction; TIMI, Thrombolysis In Myocardial Infarction.
- Dangas GD, et al. Abstract 410-10.ACC/WCC 28-30 March 2020.
- Dangas G, et al. J Am Coll Cardiol. 2020. DOI:10.1016/j.jacc.2020.03.011.
- Mehran R, et al. N Engl J Med. 2019;381(21):2032-2042.
Posted on
« COVID-19 associated with higher VTE rates relative to influenza Next Article
Crosstalk between inflammation and coagulation in severe COVID-19 infections »
Table of Contents: ACC/WCC 2020
Featured articles
Heart Failure and Cardiomyopathies
Mavacamten shows promising results in non-obstructive hypertrophic cardiomyopathy
Vericiguat shows beneficial effects in a very high-risk HF population
No role for sodium nitrite in out-of-hospital cardiac arrest
Vascular Medicine and Thromboembolism
Rivaroxaban and aspirin effective and safe for PAD patients
TAILOR-PCI misses endpoint but still provides valuable insights
Edoxaban: alternative to warfarin after surgical aortic or mitral valve procedures?
Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel
Apixaban offers new perspective for cancer patients in need of anticoagulation
Rivaroxaban superior to enoxaparin in preventing VTE in non-major orthopaedic surgery
Interventional Cardiology
TAVR safe and effective in low-risk bicuspid aortic stenosis patients
TAVR model reveals differences in hospital outcomes
2-year results show non-significant outcomes TAVR vs surgery in severe aortic stenosis
Renal denervation better than sham for blood pressure
Infusion of ethanol in the vein of Marshall for persistent AF
Atrial Fibrillation/Acute Coronary Syndrome
Fewer adverse events with ticagrelor monotherapy after 3 months DAPT
TWILIGHT sub-study: same outcomes for diabetes patients
TWILIGHT sub-study: complex PCI patients
LAAO Watchman registry data positive
Apixaban in AF patients with recent ACS/PCI: Drop aspirin after 30 days
Genetics and Prevention
Homozygous FH responds to alirocumab
Evinacumab significantly reduces LDL-C in homozygous FH patients
Higher serum levels of eicosapentaenoic acid correlate with reduced CV events
Quit smoking: vaping + counselling helps
Related Articles

ACC.20/WCC Highlights Podcast Part 2 of 3
TAILOR-PCI misses endpoint but still provides valuable insights

Letter from the Editor
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy